GP-40081 + NovoMix® 30 Penfill®
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clamp Study
Conditions
Clamp Study
Trial Timeline
Apr 15, 2019 → Jun 28, 2019
NCT ID
NCT04184492About GP-40081 + NovoMix® 30 Penfill®
GP-40081 + NovoMix® 30 Penfill® is a pre-clinical stage product being developed by GEROPHARM for Clamp Study. The current trial status is completed. This product is registered under clinical trial identifier NCT04184492. Target conditions include Clamp Study.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04184492 | Pre-clinical | Completed |
Competing Products
9 competing products in Clamp Study
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Insulin Aspart + NovoRapid® Penfill® | GEROPHARM | Pre-clinical | 15 |
| RinGlar® + Lantus® | GEROPHARM | Pre-clinical | 15 |
| Insulin Lispro Mix 25 + Humalog® Mix 25 | GEROPHARM | Pre-clinical | 15 |
| Insulin Lispro + Humalog® | GEROPHARM | Pre-clinical | 15 |
| Antithrombin gamma + physiological saline | Kyowa Kirin | Phase 3 | 77 |
| Placebo + RLX030 | Novartis | Phase 2 | 52 |
| recombinant human relaxin | Novartis | Phase 1 | 33 |
| Sildenafil citrate | Pfizer | Phase 2 | 51 |
| Furosemide | Pacific Biosciences | Phase 3 | 69 |